The development of Proteolysis Targeting Chimeras, or “PROTACs*,” has garnered significant attention in the pharmaceutical industry due to their potential to target and degrade disease-causing proteins previously considered undruggable. As a novel therapeutic modality, PROTACs offer a promising alternative to traditional small-molecule inhibitors and biologics. However, despite the excitement around these therapies, preclinical evaluations of…
Kymera Therapeutics shares positive KT-474 data for atopic dermatitis
Kymera Therapeutics (NSDQ:KYMR), like a growing number of biotech companies, is intending to expand the druggable universe. To that end, the company announced positive data related to targeted protein degradation (TPD). This modality enables oral small-molecule drugs to coax the body into clearing disease-causing proteins. Kymera’s lead drug candidate, KT-474, targets a key protein known…